ClinicalTrials.gg
Not yet recruitingNCT07341178Updated Jan 14, 2026

Acute Effects on Stem Cell Surveillance

An interventional study of Anthocyanin-rich berry extract and Anthocyanin-rich flower/leaf extract in Stem Cell Surveillance, sponsored by Natural Immune Systems Inc. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Natural Immune Systems Inc · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal for this clinical trial is to compare acute immune effects of three nutraceutical ingredients and blends to a placebo.

Read the detailed description

The goal for this clinical trial is to compare acute immune effects of anthocyanin-rich botanical extracts and blends to a placebo.

Stem cell mobilization and homing will be evaluated through monitoring of changes to the numbers of various types of stem cells in the blood circulation.

The testing will show whether consuming the active test products lead to changes in stem cell numbers in circulation above the normal circadian changes for each participant. The normal circadian changes are documented on the clinic visit where placebo is consumed. Several different stem cell populations will be evaluated using flow cytometry.

02

Conditions studied

  • Stem Cell Surveillance

Keywords

  • Stem cells
  • Flow cytometry
  • Surveillance
  • Mobilization
  • Homing
03

In context

Lead sponsor

Natural Immune Systems Inc is the lead sponsor of 25 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults;
  • Age 18-75 years (inclusive);
  • Veins easy to see in one or both arms (to allow for the multiple blood draws);
  • Willing to comply with study procedures, including:

    • Maintaining a consistent diet and lifestyle routine throughout the study,
    • Consistent habit of bland breakfasts on days of clinic visits,
    • Abstaining from exercising and nutritional supplements on the morning of a study visit,
    • Abstaining from use of coffee, tea, and soft drinks for at least one hour prior to a clinic visit,
    • Abstaining from music, candy, gum, computer/cell phone use, during clinic visits.

Exclusion criteria

Exclusion Criteria:

  • Previous major gastrointestinal surgery (absorption of test product may be altered) (minor surgery not a problem, including previous removal of appendix and gall bladder);
  • Taking anti-inflammatory medications on a daily basis;
  • Currently experiencing intense stressful events/ life changes;
  • Currently in intensive athletic training (such as marathon runners);
  • Currently taking anxiolytic, hypnotic, or anti-depressant prescription medication;
  • An unusual sleep routine (examples: working graveyard shift, irregular routine with frequent late nights, studying, partying);
  • Unwilling to maintain a constant intake of supplements over the duration of the study;
  • Anxiety about having blood drawn;
  • Pregnant, nursing, or trying to become pregnant;
  • Known food allergies related to ingredients in active test product or placebo.

Prescription medication will be evaluated on a case-by-case basis.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Crossover Group 1, randomized

    Participants consume a test product on each of the four clinic days, at least 1 week apart, allowing for 1 week wash-out period between each product. Participants will consume each of the 3 active test products versus placebo over 5 weeks, in this order: A, B, C, D.

    Dietary Supplement: Anthocyanin-rich berry extract · Dietary Supplement: Anthocyanin-rich flower/leaf extract · Dietary Supplement: Berry /leaf blend · Dietary Supplement: Placebo

  • Experimental
    Crossover Group 2, randomized

    Participants consume a test product on each of the four clinic days, at least 1 week apart, allowing for 1 week wash-out period between each product. Participants will consume each of the 3 active test products versus placebo over 5 weeks, in this order: B, C, D, A.

    Dietary Supplement: Anthocyanin-rich berry extract · Dietary Supplement: Anthocyanin-rich flower/leaf extract · Dietary Supplement: Berry /leaf blend · Dietary Supplement: Placebo

  • Experimental
    Crossover Group 3, randomized

    Participants consume a test product on each of the four clinic days, at least 1 week apart, allowing for 1 week wash-out period between each product. Participants will consume each of the 3 active test products versus placebo over 5 weeks, in this order: C, D. A, B.

    Dietary Supplement: Anthocyanin-rich berry extract · Dietary Supplement: Anthocyanin-rich flower/leaf extract · Dietary Supplement: Berry /leaf blend · Dietary Supplement: Placebo

  • Experimental
    Crossover Group 4, randomized

    Participants consume a test product on each of the four clinic days, at least 1 week apart, allowing for 1 week wash-out period between each product. Participants will consume each of the 3 active test products versus placebo over 5 weeks, in this order: D, A, B, C.

    Dietary Supplement: Anthocyanin-rich berry extract · Dietary Supplement: Anthocyanin-rich flower/leaf extract · Dietary Supplement: Berry /leaf blend · Dietary Supplement: Placebo

Interventions

  • Dietary supplementAnthocyanin-rich berry extract

    0.5 grams

  • Dietary supplementAnthocyanin-rich flower/leaf extract

    0.5 grams

  • Dietary supplementBerry /leaf blend

    0.5 grams

  • Dietary supplementPlacebo

    Placebo (white rice-based)

06

What researchers measure

Primary outcomes

  1. Stem cell surveillance

    Changes to the number of stem cells in the blood circulation (number of cells per mL blood). Data is collected on the following types of stem cells: CD45dimCD34+CD309+, CD45dimCD34+CD309-, CD31++CD34-, CD45-CD90+.

    Time frame: Baseline, 1 hour, 2 hours after consumption

Secondary outcomes

  1. Serum cytokine levels

    Time frame: Baseline, 1 hour, 2 hours after consumption

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Jan 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 14, 2026
StartEst.
Jan 2026
Primary completionEst.
Jan 2027
CompletionEst.
Mar 2027
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07341178
Lead sponsor
Natural Immune Systems Inc
Responsible party
Sponsor
First posted
Jan 14, 2026
Start date
Jan 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jan 14, 2026

Study contacts

Gitte S Jensen, PhD
Contact
Gitte@nislabs.com
541 884 0112
Alex Cruickshank
Contact
Alex@nislabs.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion